SEC Comment Letter 0000000000-25-004705 to Avenir Wellness Solutions, Inc. (CIK 0001643301)
Avenir Wellness Solutions, Inc. (CIK 0001643301)
Date: May 2, 2025 · CIK: 0001643301 · Accession: 0000000000-25-004705
AI Filing Summary & Sentiment
Letter
May 2, 2025 Joel Bennett Chief Financial Officer Avenir Wellness Solutions, Inc. 5805 Sepulveda Blvd Suite 801 Sherman Oaks, CA 91411 Re:Avenir Wellness Solutions, Inc. Form 10-K for the Year Ended December 31, 2022 Form 10-Q for the Period Ended September 30, 2023 Dear Joel Bennett: We issued comments to you on the above captioned filing on April 11, 2024. As of the date of this letter, these comments remain outstanding and unresolved. We expect you to provide a complete, substantive response to these comments by May 16, 2025. If you do not respond, we will, consistent with our obligations under the federal securities laws, decide how we will seek to resolve material outstanding comments and complete our review of your filing and your disclosure. Among other things, we may decide to release publicly, through the agency's EDGAR system, all correspondence, including this letter, relating to the review of your filings, consistent with the staff's decision to publicly release comment and response letters relating to disclosure filings it has reviewed. Please contact Christine Torney at 202-551-3652 or Kevin Vaughn at 202-551-3494 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
May 2, 2025
Joel Bennett
Chief Financial Officer
Avenir Wellness Solutions, Inc.
5805 Sepulveda Blvd
Suite 801
Sherman Oaks, CA 91411
Re:Avenir Wellness Solutions, Inc.
Form 10-K for the Year Ended December 31, 2022
Form 10-Q for the Period Ended September 30, 2023
Dear Joel Bennett:
We issued comments to you on the above captioned filing on April 11, 2024. As of
the date of this letter, these comments remain outstanding and unresolved. We expect you to
provide a complete, substantive response to these comments by May 16, 2025.
If you do not respond, we will, consistent with our obligations under the federal
securities laws, decide how we will seek to resolve material outstanding comments and
complete our review of your filing and your disclosure. Among other things, we may decide
to release publicly, through the agency's EDGAR system, all correspondence, including this
letter, relating to the review of your filings, consistent with the staff's decision to publicly
release comment and response letters relating to disclosure filings it has reviewed.
Please contact Christine Torney at 202-551-3652 or Kevin Vaughn at 202-551-3494
with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences